DEC 06, 2016 8:00 AM PST

Pre-emptive genotyping for pharmacogenomic risk - establishing a benchmark

Sponsored by: Affymetrix, Affymetrix
Speaker
  • Professor of Pediatrics, Medicine and Physiology, Chief - Section of Genomic Pediatrics, Department of Pediatrics, Medical College of Wisconsin
    BIOGRAPHY

Abstract

DATE: December 6, 2016
TIME: 8:00am PT, 11:00am ET

Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in health care. In the US alone, an estimated two million serious ADRs occur annually, causing over 100,000 deaths per year. Based on these estimates, ADRs are the 4th leading cause of death ahead of pulmonary disease, diabetes, AIDS, and pneumonia. The percentage of hospital admissions due to ADRs in some countries exceeds 10%. 

Due to the magnitude of this problem healthcare organizations and pharmaceutical companies worldwide are developing major initiatives to reduce the cost and impact of ADRs. Pre-emptive pharmacogenomic genotyping is a pivotal new approach using genetic data to gain valuable insights into metabolic status to better understand the cause of adverse events. 

Ulrich Broeckel, MD and Chief, Section of Genomic Pediatrics at the Medical College of Wisconsin, is a leader in pharmacogenomics research and will share his experience in establishing a new benchmark for pre-emptive genotyping for pharmacogenomics.

During this session you will learn:

  • How translational clinical researchers gain valuable insight into an individual’s ability to process drugs known to be actionable and where high, moderate, low, preliminary and unknown evidence exists
  • Why genotyping of highly predictive markers in genes including GSTM1, CYP1A2, CYP2D6, CYP2B6, CYP2A6, SULT1A1, CYP2C19, and CYP2C8 that are in highly homologous regions is important 
  • How copy number variation (CNV) analysis for important ADME genes is integrated into the system 

For Research Use Only. Not for use in diagnostic procedures.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
NOV 30, 2021 10:00 AM PST
C.E. CREDITS
NOV 30, 2021 10:00 AM PST
Date: November 30, 2021 Time: 10:00am (PDT), 1:00pm (EDT) The prevalence of thyroid disease worldwide has served as a catalyst for healthcare providers to study various tools and methods to...
OCT 20, 2021 10:00 AM PDT
C.E. CREDITS
OCT 20, 2021 10:00 AM PDT
Date: October 20, 2021 Time:10:00am (PDT), 1:00pm (EDT) As the prevalence of Diabetes continues to rise in many areas across the globe, healthcare providers continue to look for methods that...
NOV 17, 2021 8:00 AM PST
C.E. CREDITS
NOV 17, 2021 8:00 AM PST
Date: November 17, 2021 Time: 8:00am (PDT), 11:00am (EDT) From waste disposal to promising biomarkers and therapeutic agents, exosomes and other extracellular vesicles are valuable in resear...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 09, 2021 6:00 AM PST
C.E. CREDITS
DEC 09, 2021 6:00 AM PST
Date: December 9, 2021 Time: 6:00am (PDT), 9:00 am (EDT) As the number of biotherapeutic candidates in development is increasing, the requirements of analytical tools to understand the molec...
Loading Comments...
Show Resources